Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fermenta BiotechBOM:506414 +7.25%65 Days Inventory is 333.59 as of Mar. 2026, which is 28% above its 10-year median of 261.61. GuruFocus rates BOM:506414 with a GF Score™ of 65/100 and a GF Value™ of ₹321.75 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, Fermenta Biotech ranks worse than 79.31% on this metric.
The historical rank and industry rank for Fermenta Biotech's Days Inventory or its related term are showing as below:
BOM:506414'
s Days Inventory Range Over the Past 10 Years
Min: 170.78 Med: 261.61 Max: 443.59
Current: 270.45
During the past 13 years, Fermenta Biotech's highest Days Inventory was 443.59. The lowest was 170.78. And the median was 261.61.
BOM:506414's Days Inventory is ranked worse than 79.31% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs BOM:506414: 270.45
Fermenta Biotech's Days Inventory
increased
from Mar. 2025 (213.45) to Mar. 2026 (333.59).
It might indicate that Fermenta Biotech's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Fermenta Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.27.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fermenta Biotech's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.25.
Fermenta Biotech (BOM:506414) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Fermenta Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fermenta Biotech's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Fermenta Biotech Days Inventory Related Terms
Fermenta Biotech Days Inventory Historical Data
* Premium members only.
The historical data trend for Fermenta Biotech's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fermenta Biotech's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fermenta Biotech Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fermenta Biotech's Days Inventory distribution charts can be found below:
* The bar in red indicates where Fermenta Biotech's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fermenta Biotech (BOM:506414) has a Days Inventory of 333.59 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Fermenta Biotech and its competitors. This is 28% above median its historical median of 261.61. Over the past decade, Fermenta Biotech's Days Inventory has ranged from 170.78 to 443.59. According to the industry distribution chart, Fermenta Biotech ranks #732 out of 923 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is Fermenta Biotech's Days Inventory too high?
Fermenta Biotech's current Days Inventory of 333.59 is 28% above median its 10-year median of 261.61. Over the past 10 years, this metric has ranged from a low of 170.78 to a high of 443.59. The Drug Manufacturers industry median Days Inventory is 164.87. Fermenta Biotech's value of 333.59 is 102.3% above this industry median. Based on the distribution chart, Fermenta Biotech ranks #732 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Fermenta Biotech has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fermenta Biotech's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fermenta Biotech ranks #732 out of 923 companies for Days Inventory. This places Fermenta Biotech in the lower half of its industry. The industry median Days Inventory is 164.87. Fermenta Biotech's value of 333.59 is 102.3% above this benchmark. Historically, Fermenta Biotech's own Days Inventory has ranged from 170.78 to 443.59 over the past decade. While the company's 10-year median is 261.61 vs. the industry median of 164.87, Fermenta Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fermenta Biotech's current Days Inventory of 333.59 is 102.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Fermenta Biotech and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fermenta Biotech's current Days Inventory is 333.59, which is 28% above median its own 10-year median of 261.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fermenta Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fermenta Biotech (BOM:506414) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹321.75, compared to a current price of ₹499.30 — trading 55.2% above its estimated fair value. The current Days Inventory is 333.59, which is 28% above median its 10-year median of 261.61 and 102.3% above the Drug Manufacturers industry median of 164.87. Fermenta Biotech's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Fermenta Biotech (BOM:506414), the current Days Inventory is 333.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fermenta Biotech (BOM:506414) Overvalued in 2026?
Based on GuruFocus' analysis, Fermenta Biotech stock appears to be overvalued.
The current stock price of ₹499.30 is trading 55.2% above its estimated GF Value™ of ₹321.75.
GuruFocus considers Fermenta Biotech to be Significantly Overvalued.
Key valuation signals for BOM:506414:
Days Inventory: 333.59 (28% above median its 10-year median of 261.61)
GF Value™: ₹321.75 vs. price of ₹499.30 (55.2% above fair value)
Industry Position: 102.3% above the Drug Manufacturers median (#732 of 923)
No single metric tells the full story. See the BOM:506414 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fermenta Biotech Ltd is engaged in the business of manufacturing and marketing chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products and renting and selling properties. It is a manufacturer and supplier of Vitamin D and also supplies Penicillin G Amidase, CAL B Lipase, Polymer Supports, and enzyme technologies. The company operates in two segments namely Property and Bulk Drugs/Chemicals. The majority of the revenue comes from the Bulk Drug/Chemicals segment. Geographically, it caters to both domestic and international markets and generates maximum revenue from the Indian market.
65GF Score
Get the complete analysis for BOM:506414
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506414 has been successfully added to your 
